Closure of research units and job losses part of Novartis restructure

6 October 2016

Swiss pharma giant Novartis (NOVN: VX) is to close two research units and cut around 175 jobs as part of a new research strategy.

Groups of biologics researchers in China and Switzerland will be hit by the closures while another hub in Singapore will move to the USA in a restructure that comes a month after news that Novartis will shut its Cell and Gene Therapies Unit, affecting 120 positions at the company.

Announcing the latest planned changed, a statement from Novartis reads: “The creation of a unified early discovery research group based in Basel, Switzerland and Cambridge, USA, will be closely integrated with the Novartis Institutes for BioMedical Research (NIBR) drug discovery teams around the world.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK